Teza Capital Management’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $324K | Sell |
5,169
-3,738
| -42% | -$299K | 1.19% | 31 |
|
|
2025
Q4 | $849K | Buy |
8,907
+1,172
| +15% | +$115K | 2.73% | 4 |
|
|
2025
Q3 | $755K | Buy |
7,735
+3,101
| +67% | +$321K | 4.08% | 3 |
|
|
2025
Q2 | $498K | Sell |
4,634
-9,812
| -68% | -$993K | 0.37% | 84 |
|
|
2025
Q1 | $1.46M | Buy |
+14,446
| New | +$1.45M | 0.67% | 19 |
|
|
2024
Q4 | – | Sell |
-59,132
| Closed | -$4.96M | – | 534 |
|
|
2024
Q3 | $4.96M | Sell |
59,132
-63,934
| -52% | -$5.04M | 0.54% | 38 |
|
|
2024
Q2 | $9.48M | Buy |
123,066
+87,954
| +250% | +$6.44M | 1.16% | 4 |
|
|
2024
Q1 | $2.4M | Buy |
+35,112
| New | +$2.26M | 0.32% | 87 |
|
|
2023
Q3 | – | Sell |
-38,707
| Closed | -$2.09M | – | 603 |
|
|
2023
Q2 | $2.09M | Sell |
38,707
-86,076
| -69% | -$4.5M | 0.34% | 88 |
|
|
2023
Q1 | $6.24M | Buy |
124,783
+57,056
| +84% | +$2.69M | 1.35% | 4 |
|
|
2022
Q4 | $3.13M | Buy |
+67,727
| New | +$2.93M | 0.6% | 21 |
|
|
2022
Q3 | – | Sell |
-15,863
| Closed | -$591K | – | 541 |
|
|
2022
Q2 | $591K | Sell |
15,863
-18,993
| -54% | -$773K | 0.23% | 161 |
|
|
2022
Q1 | $1.54M | Buy |
34,856
+28,261
| +429% | +$1.22M | 0.58% | 33 |
|
|
2021
Q4 | $280K | Sell |
6,595
-799
| -11% | -$33.6K | 0.08% | 330 |
|
|
2021
Q3 | $321K | Sell |
7,394
-84,286
| -92% | -$3.73M | 0.15% | 201 |
|
|
2021
Q2 | $3.92M | Buy |
91,680
+50,007
| +120% | +$2.1M | 0.64% | 32 |
|
|
2021
Q1 | $1.61M | Buy |
41,673
+128
| +0.3% | +$4.84K | 0.32% | 92 |
|
|
2020
Q4 | $1.49M | Buy |
41,545
+23,320
| +128% | +$840K | 0.85% | 23 |
|
|
2020
Q3 | $696K | Sell |
18,225
-80,255
| -81% | -$3.09M | 0.41% | 63 |
|
|
2020
Q2 | $3.46M | Buy |
+98,480
| New | +$3.55M | 0.77% | 18 |
|
|
2020
Q1 | – | Sell |
-18,265
| Closed | -$826K | – | 169 |
|
|
2019
Q4 | $826K | Sell |
18,265
-7,593
| -29% | -$318K | 0.23% | 139 |
|
|
2019
Q3 | $1.05M | Buy |
+25,858
| New | +$1.1M | 0.27% | 122 |
|
|
2019
Q2 | – | Sell |
-6,528
| Closed | -$251K | – | 347 |
|
|
2019
Q1 | $251K | Buy |
+6,528
| New | +$249K | 0.13% | 236 |
|
|
2018
Q3 | – | Sell |
-15,001
| Closed | -$491K | – | 390 |
|
|
2018
Q2 | $491K | Buy |
+15,001
| New | +$452K | 0.07% | 372 |
|
|
2017
Q2 | – | Sell |
-74,625
| Closed | -$1.86M | – | 54 |
|
|
2017
Q1 | $1.86M | Buy |
+74,625
| New | +$1.81M | 0.54% | 32 |
|
Other funds holding BSX
VCM
VPM
Teza Capital Management's BSX Position: Q1 2026 in Review
Teza Capital Management reduced its Boston Scientific (BSX) stake by 42% in Q1 2026, selling an estimated $299K and leaving 5,169 shares worth $324K. The position accounts for 1.19% of the portfolio, ranked #31.
Teza Capital Management first reported a position in BSX in Q1 2017 and has held it in 25 quarters since. The position peaked at $9.48M in Q2 2024. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.
- Teza Capital Management held 5,169 shares of Boston Scientific worth $324K as of Q1 2026.
- Teza Capital Management sold 3,738 Boston Scientific shares in Q1 2026, an estimated $299K.
- Boston Scientific made up 1.19% of Teza Capital Management's portfolio in Q1 2026, its #31 holding.
- Teza Capital Management first reported a position in Boston Scientific in Q1 2017 and has held it in 25 quarters since.
- Teza Capital Management's Boston Scientific position peaked at $9.48M in Q2 2024.
- 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.
Based on Teza Capital Management's 13F filing for Q1 2026, filed 15 May 2026.